Under one in 10 patients that would benefit from weight-loss injections such as Wegovy are able to get them, caution the World Health Organization as it releases its initial guidance on the therapies.
With over a billion individuals worldwide now classified as obese, it is urging more widespread and fairer availability to GLP-1 medication.
According to estimates, in excess of 2,000,000,000 could be living with obesity by 2030 without intervention.
"The latest guidelines affirms that obesity is a lifelong illness that can be treated with thorough and ongoing support," stated WHO director-general Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and distribution challenges are key obstacles to widespread availability to the treatments that can help people shift significant body mass, notes the agency.
GLP-1 Therapy Supply Crisis
Even in the current best projected scenario, the supply of such drugs might only reach approximately 100 million people – fewer than 10% of eligible patients, per the WHO.
The guideline encourages governments and firms to increase access, by approaches like licensing agreements.
Exclusive production rights on the active ingredient – the primary component of the drug Wegovy – is scheduled to end in multiple nations in 2026.
How Obesity Jabs Function
GLP-1 drugs imitate a biological compound to slow digestion, reduce hunger and increase the sense of being full so users eat less.
Patients typically see weight reduction within a few weeks of beginning the regular doses.
Studies suggests users may see weight return within a year of halting the treatment, when their normal hunger return.
Being overweight or obese elevates your likelihood for contracting diseases, including diabetes, heart disease, brain attack, and some cancers.
Excess weight impacts people in countries worldwide and was linked to over three and a half million deaths worldwide in 2024, as per the health agency.
